Patent application number | Description | Published |
20090010927 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells - The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders. | 01-08-2009 |
20090143997 | Methods and compositions for cancer treatment relating to BRCA1 BRCT domain recognition of phosphorylated BACH1 - The present invention relates to compounds (e.g., peptidomimetics and non-peptides) that treat, prevent, or stabilize cellular proliferative disorders and methods of treating, preventing, or stabilizing such disorders. The invention also provides three-dimensional structures of a human BRCT domain-BACH1 phosphopeptide complex. | 06-04-2009 |
20090181468 | Methods and compositions for treating cellular proliferative diseases - The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, screening assays for identifying such compounds, and methods for treating such disorders. | 07-16-2009 |
20100030543 | Products and processes for modulating peptide-peptide binding domain interactions - The present invention relates to therapeutic compounds and methods of use of these therapeutic compounds for treating cellular proliferative disorders. The invention also provides three-dimensional structures of a Polo-like kinase and methods for designing or selecting small molecule inhibitors using these structures, and the therapeutic use of such compounds. The invention also includes a method for identifying novel phosphopeptide-binding domains. | 02-04-2010 |
20110104713 | PRODUCTS AND PROCESSES FOR MODULATING PEPTIDE-PEPTIDE BINDING DOMAIN INTERACTIONS - The present invention relates to therapeutic compounds and methods of use of these therapeutic compounds for treating cellular proliferative disorders. The invention also provides three-dimensional structures of a Polo-like kinase and methods for designing or selecting small molecule inhibitors using these structures, and the therapeutic use of such compounds. The invention also includes a method for identifying novel phosphopeptide-binding domains. | 05-05-2011 |
20120295802 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT RELATING TO BRCA1 BRCT DOMAIN RECOGNITION OF PHOSPHORYLATED BACH1 - The present invention relates to compounds (e.g., peptidomimetics and non-peptides) that treat, prevent, or stabilize cellular proliferative disorders and methods of treating, preventing, or stabilizing such disorders. The invention also provides three-dimensional structures of a human BRCT domain-BACH1 phosphopeptide complex. | 11-22-2012 |
20140037755 | Mapkap Kinase-2 as a Specific Target for Blocking Proliferation of P53-Defective Cells - The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders. | 02-06-2014 |
20140044770 | Compositions and Methods for Modulating BRD4 Bioactivity - Compositions and methods for increasing or decreasing DNA repair are provided. Composition includes a Brd4 polypeptide, fragment, fusion, or variant thereof. The fusion protein can include a protein transduction, a targeting domain, or a combination thereof to enhance delivery of the fusion protein to the interior of a particular target cell, such as a cancer cell. Inhibitory nucleic acids that target a Brd4 mRNA and antibodies that target a Brd4 polypeptide are also disclosed. The inhibitory nucleic acid or antibody can target a sequence or epitope on Brd4 isoform B that is absent on Brd4 isoform A and Brd4 isoform C. Methods for increasing or decreasing the sensitivity of cells to a DNA damaging agent, methods of treating cancer, and methods of determining cells' sensitivity to a DNA damaging agent are also disclosed. | 02-13-2014 |